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Overrepresentation of chromosomal bands 3q25–q29 has been associated with shortened disease-specific survival in head and neck
squamous cell carcinoma (HNSCC). To assess the prevalence of copy number gains (44 signals per cell) and high-level amplifications
(48 signals per cell) from putative oncogenes in this chromosomal region (CCNL1, SNO, PIK3CA, TP73L), tissue microarray analysis
was applied on 280 HNSCCs by fluorescence in situ hybridization. Overall frequency of additional copy numbers was 34.3% for
CCNL1, 31.8% for SNO, 39.0% for PIK3CA and 38.3% for TP73L, respectively. In general, gains were more frequently detected in stage
IV compared to stage I–III tumours. Performing multivariate logistic regression analysis, a significant association of CCNL1 gains and
the presence of lymph node metastases was found, which was independent of anatomical site and T-stage of the primary tumour
(P¼0.049). Site-specific subgroup analysis further showed that copy number gains of CCNL1 and SNO occurred more frequently in
oral carcinomas in advanced clinical stages as compared to N0 oral lesions (CCNL1: P¼0.03; SNO: P¼0.03). Finally, Kaplan–Meier
analysis revealed that high-level amplifications of CCNL1 correlated with shorter overall survival of the patients. Our results indicate
that CCNL1 plays a critical role in the loco-regional progression of HNSCC and may serve as an indicator for occult advanced tumour
stages.
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Squamous cell carcinoma of the head and neck (HNSCC)
represents the sixth most common human neoplasm.
Despite novel combined adjuvant and neoadjuvant therapeutic
approaches, the 5-year survival rate did not exceed 55% during
the last decade (Landis et al, 1999). Therapeutic decisions are
usually based on clinicopathological parameters like TNM
stage and histological grading, which, however, often fail to
predict patients’ outcome. Therefore, there is a need to better
understand HNSCC development on the molecular level. This
should lead to an improved stratification between higher- and
lower-risk patients, which can be treated in a more selective
and individualised manner. Furthermore, understanding molecu-
lar pathomechanisms might identify therapeutical inter-
ference points.
Copy number gain on chromosome 3 with a minimal over-
lapping area of bands 3q25-qter is a recurrent molecular
alteration in HNSCC (Speicher et al, 1995; Weber et al, 1998).
According to Bockmu ¨hl et al (2000), this aberration is correlated
with a decreased overall survival. The corresponding chromosomal
region harbors several potential proto-oncogenes, as for example,
TP73L, PIK3CA, SNO and CCNL1, which may contribute to a more
aggressive tumour progression. TP73L is a member of the P53 gene
family and found overexpressed in various HNSCC cell lines (Hibi
et al, 2000). PIK3CA, which is involved in multiple cancer-
related functions like cell survival, proliferation and cell
migration (Iyer et al, 1999; Guhaniyogi and Brewer, 2001), was
considered to play a role in early HNSCC tumorigenesis
since genomic amplifications were detected in precancerous oral
dysplasias (Redon et al, 2002). Increased expression of
PIK3CA, however, failed to predict clinical outcome in a small
collection of primary HNSCC (Yang et al, 1998). SNO (SKI-
related novel gene) includes two distinct genes, SNO-A and
SNO-N, the latter one being a component of the TGFb/SMAD
pathway (Stroschein et al, 1999). Amplifications of the gene
were previously detected in primary oesophagus squamous
cell carcinoma (Imoto et al, 2001). Finally, CCNL1 (also
termed Cyclin L1 and Ania-6a) codes for a putative key regulator
of pre-mRNA processing and is involved in G0 to G1 transition
during the cell cycle (Iyer et al, 1999; Berke et al, 2001). In
a recent study, it has been shown to be located on a small
region highly amplified in a HNSCC-derived cell line and to
be overexpressed in HNSCC primary tumours (Redon et al,
2002).
In the present study, 280 clinically well-defined HNSCCs
biopsies mounted on a tissue microarray were analysed for copy
number changes of CCNL1, SNO, PIK3CA and TP73L by
fluorescence in situ hybridisation (FISH). In this way, we wanted
to assess the role of each of these candidate genes with regard to
aggressive progression and unfavourable clinical outcome of
HNSCC.
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In total, 280 primary, paraffin-embedded HNSCC, 124 oral
squamous cell carcinomas (OSCC), 96 pharyngeal squamous cell
carcinomas (PSCC) and 60 laryngeal squamous cell carcinomas
(LSCC) were obtained from the archives of the Institute of
Pathology, University of Heidelberg. For all tumours, histopatho-
logical and clinical follow-up data were available. Head and neck
squamous cell carcinomas were graded according to the TNM
system and the UICC stage. Uvula mucosa tissue from healthy
donors was used as reference for FISH experiments. The study was
approved by the Medical Ethics Commission, University of
Heidelberg.
TMA construction, FISH analysis and statistical evaluation
Generation of TMAs was performed as previously described
(Freier et al, 2003). Briefly, HE-stained sections were cut from each
block to define representative tumour regions. Small tissue
cylinders with a diameter of 0.6mm were taken from selected
areas of each donor block using a tissue chip microarrayer
(Beecher Instruments, Silver Spring, MD, USA) and transferred to
a recipient paraffin block. In all, 280 different tumour specimens
and 10 control samples were arrayed. The recipient paraffin block
was cut in 5-mm paraffin sections using standard techniques.
For FISH experiments, BAC clones RP11-555M1 (CCNL1), RP11-
373I6 (TP73L), RP11-245C23 (PIK3CA) and RP11-543D10 (SNO),
obtained from the Resource Center and Primary Database,
Germany (RZPD), were used as probes. Clones were prepared
from bacterial cultures using Qiagen-Plasmid-Kit
s (Qiagen
GmbH, Germany) and labelled by nick translation with cyanine-
3-dUTP (Perkin-Elmer Life Science, Boston, MA, USA). As internal
control, BAC clone RP11-101p149 (chromosome 12q24) was
differentially labelled with fluorescein-12-dUTP and co-hybridised.
TMA slides were first deparaffinised in xylene, immersed in 0.2 N
HCl, and incubated in 1 M sodium thiocyanate solution at 801C for
30min. Subsequently, they were digested in a protease solution
(0.5mgml
 1 in 0.9% NaCl, pH 2.0) for 20min at 371C. Slides were
post-fixed in 10% buffered formalin for 10min, dehydrated in
ethanol and air-dried. For FISH experiments, 200ng of labelled
probe and control DNA, respectively, were added to a TMA slide in
a hybridisation solution containing 50% deionised formamide,
10% dextran sulphate, 2  SSC, 2mg salmon sperm DNA, and
10mg Cot-1 DNA. The TMA slide and probe DNA were
denaturated at 751C for 10min and hybridised overnight in a
humidified chamber at 371C. Subsequently, the slides were washed
three times in 50% deionised formamide/2  SSC at 421C for
10min and three times in 2  SSC at 421C for 5min. Interphase
nuclei were counterstained with 0.5mgml
 1 4,6-diamidino-2-
phenylindole (DAPI) in Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA).
For evaluation of the experiments, hybridisation signals from 25
nonoverlapping interphase cell nuclei of each tumour sample were
counted using a fluorescence microscope. A copy number gain was
scored, if the average number of signals per nucleus was between 4
and 8, while a high level amplification was defined as more than 8
signals per cell or if clusters of multiple signals were visible.
Fisher’s exact test and the w
2 test were performed in order to
compare the prevalence of gene copy number gain according to
anatomic site, T-stadium, stage and the presence of lymph node
metastases. Multivariate logistic regression analysis using the
statistical package SPSS (SPSS, Munich, Germany) was applied to
all patients with complete clinicopathological data sets. For overall
survival analysis, Kaplan–Meier curves of HNSCC subgroups were
analysed by log rank test. To examine the relative impact of
oncogene copy number gains on the overall survival of the
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Figure 1 Localisation of the genes analysed on chromosome 3q25–q29.
Figure 2 Detection of gene copy number gains by FISH in HNSCCs.
Low-level copy number gain of PIK3CA (top) and high-level amplification of
CCNL1 (bottom).
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spatients, a Cox proportional hazards regression model was applied
for each oncogene with anatomic site and UICC stage as co-
variables. P-values p0.05 were considered as statistically sig-
nificant in all analyses.
RESULTS
A total of 280 HNSCC tumours from 280 patients were analysed by
FISH for copy number changes of proto-oncogenes CCNL1, SNO
PIK3CA and TP73L located on chromosomal band 3q25–q29
(Figures 1 and 2). The overall frequency and results from
univariate statistical analyses are summarised in Table 1. A
significant difference in the prevalence of numerical changes was
observed in HNSCC of different anatomical sites, with PSCC
exhibiting more copy number gains than LSCC and OSCC (CCNL1
and SNO: Po0.001; PIK3CA: P¼0.003; TP73L: P¼0.007). With
regard to the clinical stage, the prevalence was significantly higher
in stage IV carcinomas as compared to stage I–III carcinomas
(CCNL1: Po0.001; SNO: P¼0.05; PIK3CA: P¼0.009; TP73L:
P¼0.03). Finally, concerning lymph node metastases, CCNL1
and TP73L showed an increased frequency of gains (CCNL1:
P¼0.02; TP73L: P¼0.05), while for SNO and PIK3CA no such
correlation was observed.
To create a multivariate model describing the risk for lymph
node metastases, additional clinical parameters were investigated
by univariate analysis. A significant association with the pre-
valence of lymph node metastases was found for higher T-stage
(T3/4 vs T1/2; Pp0.001), for younger age (o60 years vs460 years;
P¼0.005) as well as for pharyngeal localisation vs oral cavity vs
laryngeal localisation (Pp0.001). These parameters as well as gain
of CCNL1 and TP73L were included in further multivariate
analyses. The backward and the forward procedures for variable
inclusion/exclusion within the logistic regression model deter-
mined pharyngeal localisation (Pp0.001), higher T-stage
(Pp0.001) and CCNL1 copy number gain (P¼0.049) as indepen-
dent predictors for metastasis formation in HNSCC.
Since HNSCC within the pharynx, lanrynx or oral cavity are
different with regard to several clinical parameters (see below), a
detailed analysis of the respective genes was performed in OSCC,
PSCC and LSCC, separately. In OSCC (n¼85), CCNL1 and SNO
copy number gains were primarily detected in tumours exhibiting
lymph node metastases (CCNL1: P¼0.03; SNO: P¼0.03). In
addition, gains of these genes occurred at higher frequencies in
stage IV OSCC as compared to stage I–III OSCC (CCNL1: P¼0.02;
SNO: P¼0.03) (Figure 3). No such association for any of the
oncogenes was found in PSCC (n¼69) and LSCC (n¼41) (data
not shown).
Regarding the clinical outcome, a significant correlation
between shortened overall survival and higher T-stage (T3/4 vs
T1/2; Pp0.001), tumour site (pharyngeal vs laryngeal vs oral
cavity; P¼0.008) and advanced N-stage (N1–3 vs N0; Pp0.001)
was found in Kaplan–Meier analysis, whereas no such association
for gains of any of the candidate genes was detected (P40.05).
These results were confirmed by multivariate survival analyses
including the genes’ numerical status, N-stage (N0 vs N1–3), T-
stage (T1/2 vs T3/4), tumour site (pharyngeal vs laryngeal vs oral
cavity) and age in the Cox proportional hazard models, where only
the presence of lymph node metastases (Pp0.001) and higher T-
stage (P¼0.009) were significant predictors of shortened overall
survival.
Since high-level amplifications might have a stronger impact on
tumour formation and biological behaviour than low-level copy
number gains (for definition, see Material and Methods), their
influence on the clinical course was analysed separately. Although
the absolute number of high-level amplifications of the genes
analysed was rather low (see Table 1), a correlation with
unfavourable clinical course in Kaplan–Meier analysis was found
for CCNL1 (log-rank test, P¼0.006, Figure 4), but not for the
remaining genes (all P-values 40.05).
Table 1 Frequency of copy number gains of CCNL1, SNO, PIC3CA and TP73L as well as corresponding P-values for univariate subgroup analysis
CCNL1 SNO PIK3CA TP73L
HNSCC n¼280 34.3% (74/216); (3.2%) (7/216) 31.8% (69/217); (2.8%) (6/217) 39.0% (85/218); (6.0%) (13/218) 38.3% (86/224); (3.1%) (7/224)
OSCC n¼124 13.5% (13/96) 11.2% (11/98) 26.4% (24/91) 28.0% (28/100)
PSCC n¼96 56.2% (41/73) 49.3% (34/69) 51.3% (41/80) 51.4%) (38/74)
LSCC n¼60 42.6% (20/47) 48.0% (24/50) 42.6% (20/47) 40.0% (20/50)
P-values o0.001 o0.001 0.003 0.007
T1/2 n¼101 27.3% (21/77) 28.8% (23/80) 30.4% (24/79) 33.7% (29/86)
T3/4 n¼148 39.8% (47/118) 33.6% (39/116) 43.9% (50/114) 41.0% (48/117)
P-values 0.091 0.533 0.071 0.309
N0 n¼80 23.5% (16/68) 28.1% (18/64) 30.5% (18/59) 28.6% (20/70)
N1–3 n¼169 40.9% (52/127) 33.3% (44/132) 41.8% (56/134) 42.9% (57/133)
P-values 0.018 0.515 0.151 0.049
SI-III n¼75 19.0% (12/63) 21.9% (14/64) 23.6% (13/55) 26.9% (18/67)
SIV n¼174 42.4% (56/132) 36.4% (48/132) 44.2% (61/138) 43.0% (59/136)
P-values 0.001 0.049 0.009 0.031
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Figure 3 Frequency of CCNL1 and SNO copy number gains in OSCC
(SI–III and SIV: CCNL1 P¼0.02, SNO P¼0.03; N0 vs N1–3: CCNL1
P¼0.05, SNO P¼0.05).
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In the present study, the tissue array approach was applied in
order to analyse copy number gains of putative oncogenes on a
collection of 280 clinically well-documented HNSCC. We found
significant associations between clinical parameters and copy
number gains of four candidate genes, TP73L, PIK3CA, SNO and
CCNL1 located on chromosomal arm 3q. In general, frequencies of
copy number gains were between 31.8% (SNO) and 39.0% (TP73L).
Pharyngeal tumours (PSCC) showed the highest frequency in this
respect, and this was significant on the univariate as well as on the
multivariate levels (i.e. independent of the tumour size and
metastasis status). It is well known that, in contrast to laryngeal
and OSCCs, PSCCs are more aggressive, since they exhibit a higher
tendency to metastasise and are associated with decreased overall
survival (Baatenburg de Jong et al, 1993). A dosage effect of the
analysed genes might therefore well contribute to this aggressive
phenotype.
One of the major aims of this study was to search for a
molecular marker, which is associated with a higher tendency of
lymph node metastasis formation. Such a marker should be highly
useful during the initial tumour staging and might give additional
information concerning the presence of occult metastases. We
found CCNL1 to be more frequently increased in copy number in
HNSSC with loco-regional metastases, irrespective of anatomic site
and T-stage. Such an impact of CCNL1 was also detected in OSCCs
when analysed separately from PSCC and LSCC, suggesting that
CCNL1 could serve as a molecular indicator for loco-regional
metastasis formation in HNSCC. In order to confirm this, however,
further prospective studies have to be performed.
CCNL1 was also interesting with respect to overall survival, in
that high-level gene amplification (48 signals/cell) was primarily
detected in patients with lower survival rates. It should be noted
that high-level amplification of CCNL1 was found to be a rather
rare event and therefore the number of cases is still low, not
allowing a more rigid multivariate testing. Of note, this result
shows that high-level amplifications of individual genes, in
contrast to low-level gains, contribute to a distinct clinical
behaviour and therefore both of these parameters might be
considered separately in this type of analysis.
The molecular mechanisms which promote tumour progression
by CCNL1 remain to be determined. Up to now, only little is
known about its function. CCNL1, like the closely related protein
CCNL2, contain a N-terminal cyclin box but differs from the other
members of the cyclin family by the presence of a so-called RS-
domain, which is a hallmark of proteins involved in pre-mRNA
processing (de Graaf et al, 2004; Yang et al, 2004). Both proteins
were recently found to be colocalised with the splicing factor SC35
within nuclear speckles. CCNL1 was also identified as an
immediate early gene after induction of several growth factors
including epidermal growth factor (Berke et al, 2001), and there is
evidence that it is involved in G0 to G1 cell cycle progression (Iyer
et al, 1999). Recently, CCNL1 has been detected within a small
amplicon on chromosome 3q25.3 in the HNSCC cell line CAL 27.
Subsequent expression analyses revealed that it is recurrently
overexpressed in primary HNSCC (Redon et al, 2002). Our data
underline the pathogenic role of CCNL1 in HNSCC progression,
since an increased copy number of this gene was associated with
the formation of loco-regional metastases and an unfavourable
clinical outcome.
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